No evidence for association of the systemic lupus erythematosus-associated ITGAM variant, R77H, with rheumatoid arthritis in the Caucasian population SIR, A non-synonymous integrin--M (ITGAM) variant (R77H) confers a strong risk for SLE in Caucasian, African and Hispanic populations [odds ratio (OR) meta ¼ 1.83] [1, 2] . ITGAM encodes the -chain subunit of integrin-M 2 , a cell surface receptor expressed predominantly on monocytes and neutrophils, which mediates activation, adhesion and migration of leucocytes through the endothelium, as well as phagocytosis of complementcoated particles, and neutrophil apoptosis [3] . Interaction of integrin-M 2 with intercellular adhesion molecules (ICAMs) mobilizes leucocytes to sites of inflammation, and in silico modelling suggests that the R77H substitution may alter the 1 domain that binds ICAM-1 [1, 3] . Polymorphism of ICAM-1 is implicated in susceptibility to RA: a K469E variant (rs5498) in ICAM-1 is associated with RA in Korean [4] and UK sample sets [5] , but not in an Italian sample set [6] .
SLE and RA are systemic autoimmune diseases that are known to share common genetic susceptibility through the 620W variant of PTPN22 [7] , rs75674865 within STAT4 and several variants within TNFAIP3 [8] . We therefore tested for association of ITGAM R77H (rs1143679) with susceptibility to RA in Caucasian sample sets drawn from New Zealand (NZ) and the UK, including the Wellcome Trust Case Control Consortium (WTCCC).
A total of 746 NZ European Caucasian RA patients and 564 healthy controls were genotyped for rs1143679 using a Taqman single nucleotide polymorphism (SNP) genotyping assay (Applied Biosystems, Foster City, CA, USA) on the Lightcycler 480 realtime PCR system (Roche, Indianapolis, IN, USA). The NZ Caucasian population is primarily descended from British immigrants. Genetic similarity is supported by the similar allele frequency of the RA-associated PTPN22 620W variant (9.9% in our NZ control samples [9] , and 9.6% in WTCCC controls [5] ). This variant is known to differ in frequency within Europe, with frequency increasing from south to north. All cases satisfied the ACR criteria for RA, and 66% of the patients were females. Of those patients for whom serological data were available, 83% (543/654) were RF positive, and 67.6% (276/408) were anti-cyclic citrullinated peptide (anti-CCP) antibody positive. All participants gave their written informed consent, and the NZ Multi-region Ethics Committee and the Lower South Ethics Committee approved the study.
The UK WTCCC study genotyped two SNPs within ITGAM, not including rs1143679 or any SNP in high linkage disequilibrium (LD). We could not impute rs1143679 for the WTCCC data because the necessary haplotypic data were not available from HapMap. Therefore, we imputed genotypes for 1861 WTCCC RA cases and 2938 controls for all other SNPs within ITGAM using impute [10] . We also included 729 RA cases from Oxford in the UK sample set that were genotyped for rs1143679 as described above. All Oxford patients satisfied the ACR criteria for RA, and gave written informed consent. The sample comprised 71% females and 79% (567/720) were RF positive. The Oxford Research Ethics Committee granted study approval. Using the minor allele frequency (MAF) of the European-American SLE control group (0.11), and the allelic OR (1.73) [1], the NZ sample set has 98.7% power and the UK has 100% power at ¼ 0.01 to detect an equivalent association. Association analysis was performed using PLINK (pngu.mgh.harvard.edu/$purcell/plink/).
All NZ rs1143679 genotypes were in Hardy-Weinberg equilibrium (Table 1) . We did not observe a statistically significant difference in allele and genotype frequencies between the RA case and control samples (allelic P ¼ 0.72; OR ¼ 0.95; 95% CI 0.73, 1.24). Previously, six SNPs (rs9936831, rs9888879, rs12928810, rs9888739, rs11860650 and rs6565227) within ITGAM that are in very high LD with rs1143679 (r 2 values approaching 1) have been reported in a European-American sample set [2] . The WTCCC imputed data for these SNPs are presented in Table 1 . None of the SNPs demonstrated a significant difference in allele or genotype frequency between RA patients and controls (smallest allelic P ¼ 0.20 for rs9888879 and rs12928810; OR ¼ 1.09; 95% CI 0.95, 1.26). Using these SNPs as proxies for rs1143679, the WTCCC data indicate that this SNP also does not alter the risk for RA in this cohort.
Stratification on RF and CCP status did not indicate any significant differences in the rs1143679 genotype distribution for NZ RA cases (RF: P ¼ 0.38; CCP: P ¼ 0.78). Nor was a significant difference observed between RF-positive and RF-negative Oxford cases (P ¼ 0.44) ( Table 1) . Serological data on the WTCCC samples were unavailable.
We used STATA 8.0 (http://www.stata.com) to meta-analyse the NZ and UK data (using imputed SNP rs9888879 as a proxy for rs1143679 in the WTCCC) ( Table 1 ). The combined analysis confirms that there is no significant difference in the MAFs of cases vs controls (P meta ¼ 0.51; OR meta ¼ 1.05; 95% CI 0.93, 1.17).
In conclusion, there is no evidence from a combined analysis of 3336 cases and 3502 controls to support association, at a similar strength as observed in SLE, of the ITGAM variant, R77H, with RA in the Caucasian population. However, we cannot eliminate the possibility of a weaker effect for this variant in RA. Genotyping this variant in additional RA case-control sample sets is justified.
Rheumatology key message
The strongly SLE-associated R77H (rs1143679) ITGAM variant does not confer a similar risk to RA in the Caucasian population. . From a classification perspective, the current approach of attributing NP manifestations in SLE patients may be appropriate; however, from a pathogenic standpoint, any misclassification will affect the advance in the knowledge of the pathogenic mechanisms, their diagnosis and treatment. Therefore, it is important to know whether the inflammatory profile in NP manifestations due to lupus, with and without associated factors, is similar. We studied 35 patients (ACR criteria) [2] with central NP manifestations (cNPSLE) with and without associated factors. They were evaluated at hospitalization and 6 months later, with a cerebrospinal fluid (CSF) sample at both times in which IgG ANA, anti-dsDNA, anti-ribosomal-P, aCL, anti-2 glycoprotein-I and anti-N-methyl-D-aspartate receptor antibodies, as well as cytokines IL-2, -4, -6, -10, TNF-, IFN-and -and chemokines MCP-1, regulated on activation normal T cell expressed and secreted, IL-8, monokine induced by interferon gamma and gamma interferon inducible protein (IP-10) were tested. The study was approved by the Institutional Committee of Biomedical Research, and all patients provided informed consent. Of the SNPs rs9888879 and rs11860650 are in complete LD with rs12928810 and rs6565227, respectively, in the HapMap CEU population. Therefore, the data for the first two are presented here.
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d rs9888879 is in high LD with rs1143679 (r 2 approaching 1) [2] , and therefore acts as a proxy SNP in WTCCC data for rs1143679 which cannot be imputed directly.
e The Breslow-Day test for heterogeneity revealed no evidence for a difference between the NZ and UK sample sets (P ¼ 0.478).
f RF and CCP status data were available for 87.7% (654/746) and 54.7% (408/746) of the NZ cases. RF status data were available for 98.8% (720/729) of the Oxford cases.
